OXiGENE, Inc., a clinical-stage biopharmaceutical company developing therapeutics to treat cancer and eye diseases, will restructure in an effort to focus resources on its most promising early-stage clinical programs and to further cut costs. The company is cutting 11 full-time equivalent employees, or approximately 61% of its staff, and will seek to reduce the amount of space it currently rents to conduct its operations. The company anticipates recording a total charge of approximately $1.2 mi...